Condition: Acute Myeloid Leukemia · Acute Lymphoblastic T-cell Leukemia · Mixed Phenotype Acute Leukemia · Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic stem cell transplantation in a cohort of pediatric and young adult patients with chemorefractory or minimal residual disease (MRD) positive acute leukemia.
This description comes directly from the study's public registry record.
Timofei Y Zavidnyi, MD · +79153492188 · timofey.zavidnyy@dgoi.ru
Always discuss trial participation with your own doctor first.
| Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology | Moscow, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07256210